Quotient Sciences Header

Quotient Sciences Header

X

Find Approved Endocrinology Drugs in Clinical Development in CHINA

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Visen Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to D...

Details:

Top-line results of TransCon hGH, from the trial indicate that lonapegsomatropin was well-tolerated and with comparable safety to daily growth hormone. The safety profile of lonapegsomatropin in Chinese children with GHD was consistent.

Lead Product(s): Lonapegsomatropin

Therapeutic Area: Endocrinology Product Name: TransCon hGH

Highest Development Status: Approved Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 23, 2022

ASK
US

Upload
your Pipeline Activity

BeiGene

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

Details:

The stratagic collaboration between Amgen and BeiGene will significantly accelerate Amgen's plans to expand its oncology presence in China.

Lead Product(s): Denosumab

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Amgen Inc

Deal Size: $2,800.0 million Upfront Cash: $2,800.0 million

Deal Type: Collaboration January 02, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY